Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases

Autor: Timothy M Illidge, Wojciech Jurczak, Antonio da Silva, Stanley Cohen, Jutta Amersdorffer

Publikováno v: Jurczak, W, Cohen, S, Illidge, T M, Silva, A D & Amersdorffer, J 2019, ' Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases ', Future oncology (London, England), vol. 15, no. 36, pp. 4223-4234 . https://doi.org/10.2217/fon-2019-0430

Sandoz rituximab (SDZ-RTX; Rixathon®; GP2013), a rituximab biosimilar, was approved in June 2017 in Europe in all indications of reference rituximab. The stepwise SDZ-RTX development program generated extensive physicochemical, structural, functiona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f986f8bfd7d17704bd022d46c674ac7
https://pubmed.ncbi.nlm.nih.gov/31718287

Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

Autor: S. Alexeev, E. Munhoz, K. Setty Govindbabu, A. Luiza, Juliana Pereira, D. Osmanov, Wojciech Jurczak, I. Moreira, M-A. Echeveste, Pratyush Giri, Peijuan Zhu, N. Castro, O. Harlin, S. Alexandrova, Jutta Amersdorffer, A. Zubel

Publikováno v: Annals of Oncology. 28:v355

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18d63a8854016da8cc6c44671e7c7a38
https://doi.org/10.1093/annonc/mdx373